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Caveolin-1 (Cav-1), a major structural compo-
nent of cell membrane caveolae, is involved in 
a variety of intracellular signaling pathways as 
well as transmembrane transport. Cav-1, as a 
scaffolding protein, modulates signal trans-
duction associated with cell cycle progression, 
cellular senescence, cell proliferation and 
death, lipid homeostasis, etc. Cav-1 is also 
thought to regulate the expression or activity 
of oncoproteins, such as Src family kinases, 
H-Ras, protein kinase C, epidermal growth 
factor, extracellular signal-regulated kinase, 
and endothelial nitric oxide synthase. Because 
of its  frequent overexpression or mutation in 
various tumor tissues and cancer cell lines, 
Cav-1 has been speculated to play a role as 
an  oncoprotein  in cancer development and 
progression. In contrast, Cav-1 may also func-
tion as a tumor suppressor, depending on the 
type of cancer cells and/or surrounding 
 stromal cells in the tumor microenvironment 
as well as the stage of tumors.
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4.1  Introduction
Caveolae represent a flask-shaped invagination 
of the plasma membrane that play a role in endo-
cytosis and forming vesicles in the cytoplasm. 
Caveolae are heterogeneous in normal and tumor 
cells, and they are most abundant in stromal cells, 
such as adipocytes, fibroblasts, vascular endothe-
lial cells, and smooth muscle cells [1, 2]. A family 
of integral membrane proteins, called caveolins, are 
the principal components of caveolae. Caveolins 
may act by compartmentalizing and concentrating 
signaling molecules and are involved in receptor-
independent endocytosis [3]. Caveolins have 
amino-terminal and carboxy- terminal domains 
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localized at the cytoplasmic face of the cell mem-
brane (Fig. 4.1a) [4]. Caveolins also contain the 
caveolin scaffolding domain required for binding 
to signaling proteins. Caveolins modulate func-
tions of several signaling molecules, such as Src, 
G-protein α-subunits, and H-Ras, involved in cell 
proliferation and growth (Fig. 4.1b) [5]. Caveolins 
consist of the three core members, Caveolin-1 
(Cav-1), Caveolin-2 (Cav-2), and Caveolin-3 
(Cav-3). Cav-1 is highly expressed in various 
cells, such as adipocytes, endothelial cells, fibro-
blasts, and smooth muscle cells. Cav-2 shares a 
similar expression profile with Cav-1, as it 
requires Cav-1 for stabilization. Cav-3 is pre-
dominantly expressed in muscle cells [6]. Cav-1 
and Cav-3 form homo-oligomers, and oligomer-
ization is essential for caveolae biogenesis. 
Ablation of Cav-1 and Cav-3 causes a deficiency 
of caveolae in various cell types [7, 8]. Besides 
formation of caveolae, caveolins have multiple 
cellular functions by interacting with signaling 
molecules, such as receptors, kinases, adhesion 
Fig. 4.1 Structures of caveolae and Cav-1. (a) The dia-
grams of caveolae and Cav-1. Cav-1 is inserted into the 
caveolar membrane, with the N- and C-termini facing the 
cytoplasm and an intramembrane domain embedded 
within the membrane bilayer. (b) The sequence of the 
caveolin-scaffolding domain (CSD; residues 82–102) and 
the caveolin binding sequence motifs within several 
caveolae- localized signaling molecules are shown. These 
include epidermal growth factor receptor (EGF-R), Src 
family tyrosine kinases, endothelial nitric oxide synthase 
(eNOS), G-protein α subunits (Gi2α), and PKC isoforms 
(PKCα). In most cases, such interaction is inhibitory, 
leading to inactivation of the signaling molecules and 
modulation of downstream signal transduction
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molecules, and G proteins. These include choles-
terol homeostasis, vesicle trafficking, and endo-
cytosis [9, 10]. Of three isoforms of caveolin 
family, Cav-1 is the principal structural compo-
nent of caveolae, and its expression is essential 
for driving  the formation of morphologically 
identifiable caveolae [10]. Cav-1, as a scaffolding 
protein, modulates multiple signal transduction 
pathways involved in cell cycle progression, cel-
lular senescence, cell proliferation and death, 
lipid homeostasis, etc.
Over the past years, there has been increasing 
concern about the involvement of Cav-1  in the 
development and pathogenesis of human cancer. 
Cav-1 regulates cancer cell metabolism, prolif-
eration, differentiation, resistance to apoptosis, 
survival, adhesion, migration, invasion, and 
metastasis [12–16]. On the other hand, Cav-1 can 
also act as a tumor suppressor in some circum-
stances in which its low expression favors tumor 
progression [17–20]. Besides epithelial Cav-1 in 
tumors, altered expression of stromal Cav-1  in 
the tumor microenvironment (TME) is observed 
in different types of human malignancies [12, 
14]. However, the clinical significance of 
Cav-1 in cancer is still elusive.
This review summarizes the differential roles 
for Cav-1  in tumor development, migration, 
metastasis, therapy resistance, and cancer cell 
survival.
4.2  Cav-1 Expression in Human 
Cancer
Cav-1 expression has been extensively examined 
in various tumor specimens from cancer patients 
as well as in human cancer cell lines [14–18]. In 
most studies, the association between Cav1 
expression levels and clinicopathological signifi-
cance in terms of prognosis, metastatic status, 
and/or tumor resistance has been analyzed [14–
18]. However, there is a contradictory profile of 
the Cav-1 expression in human cancer [19]. 
While some studies suggest the oncogenic func-
tion of Cav-1, loss or low expression of Cav-1 
has been associated with poor outcomes in vari-
ous tumor types. In other studies, however, there 
is no consistent change in Cav-1 expression 
between cancer cells and their normal adjacent 
cells. Therefore, the effects of Cav-1 expression 
on tumorigenicity and aggressiveness appear to 
vary widely among different cancer types [19].
4.2.1  Oncogenic Function
Cav-1 is frequently overexpressed or mutated in 
various tumor tissues and cancer cell lines. 
Aberrant upregulation of Cav-1 has been postu-
lated to favor cancer cell survival and growth. 
Cav-1 may function as an oncoprotein com-
monly associated with enhanced malignant 
behavior, such as metastasis [15, 16, 18] and 
therapy resistance [14, 15, 17]. The clinicopath-
ologic significance of upregulated Cav-1 is 
described below.
4.2.1.1  Role in Cancer Cell Invasiveness 
and Metastasis
In certain tumors, progression into a metastatic or 
drug-resistant form has been attributable to reex-
pression of Cav-1 [14–18]. Upregulation of 
Cav-1 is thought to contribute to cancer cell inva-
siveness and resistance to anoikis, properties that 
are essential for metastasis [20]. In non- neoplastic 
gastric mucosa, Cav-1 was not expressed in the 
epithelial compartment. However, the expression 
of Cav-1 was significantly correlated with cancer 
progression and poor prognosis in gastric cancer. 
This was associated with an advanced stage and 
lymph node metastasis [21].
Restoration of Cav-1 expression in lung ade-
nocarcinoma cells is sufficient to promote their 
filopodia formation, migration, and metastatic 
potential [22]. Recent studies have indicated that 
cell invasion during tumor progression may be 
critically dependent on the acquisition of 
epithelial- mesenchymal transition (EMT) fea-
tures. Multiple lines of evidence support that 
Cav-1 mediate the invasion and metastasis of 
cancer which are accompanied by EMT.  Thus, 
Cav-1 can promote bladder cancer metastasis by 
inducing EMT which is linked to activation of 
phosphatidylinositol 3-kinase-Akt and upregula-
tion of Slug expression [23]. Moreover, overex-
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pressed Cav-1 increased vimentin expression, but 
downregulated E-cadherin. This accompanied 
the change of EMT, resulting in the increased 
motility and invasiveness in hepatocellular carci-
noma [24]. The reduced levels of Cav-1  in 
hypoxia stimulate activation of epidermal growth 
factor receptor and consequently STAT3. This, in 
turn, results in the downregulation of E-cadherin 
and upregulation of mesenchymal markers, such 
as Slug, α-smooth muscle actin, N-cadherin, and 
vimentin, suggesting that Cav-1 can mediate the 
EMT and promote invasiveness in gastric cancer 
[24] (Fig. 4.2).
Matrix metalloproteins (MMPs) are a family 
of zinc-containing proteolytic enzymes that 
degrade various components of extracellular 
matrix [25]. The migration- and invasion- 
promoting effects of Cav-1 overexpression in 
hepatocellular carcinoma appear to be mediated 
by increasing secretion or expression of MMP-2, 
MMP-9, and MT1-MMP as well as inducing an 
EMT-like phenotype [26].
Rho-GTPases are involved in tumor metasta-
sis and invasion [27, 28]. Previous studies have 
indicated the role of Cav-1  in regulating the 
activity of Rho-GTPases in various metastatic 
cancers. The interaction between Cav-1 and Rho- 
GTPases promotes tumor metastasis, which 
depends on the elevated expression of α5-integrin 
and the enhanced activation of Src and Ras [29]. 
The acquisition of the metastatic phenotype 
requires adhesive interaction between cancer 
cells and the endothelium, in which focal adhe-
sion kinase (FAK) plays an essential role [30]. 
The expression of Cav-1 was positively corre-
lated with that of FAK in gastric cancer [21]. 
Rho/ROCK signaling promotes tumor cell migra-
tion and metastasis by regulating focal adhesion 
dynamics through Cav-1 phosphorylation at the 
tyrosine 14 residue [31]. Cav-1 tyrosine phos-
phorylation is dependent on Src kinase and Rho/
ROCK signaling. The phosphorylated Cav-1 sta-
bilizes FAK association with focal adhesion and 



















Survival and growth of
metastatictumorEndowing MET
Fig. 4.2 Cancer cells within the primary tumor undergo 
EMT and acquire stem-like traits (CSCs) and endow inva-
sive capacity, then intravasate into the tumor vasculature 
in the form of circulating tumor cells (CTCs), which must 
be able to survive the circulating blood and evade from the 
innate immune response and other defenses. Once CTCs 
migrate to a secondary site, the settlement in supportive 
niches enables them to survive and retain their stem-like 
tumor-initiating capacity. In the target site, disseminated 
cancer cells (DTCs) encounter inhibitory signals resulted 
in the arrested in cell cycle subsequently leading to dor-
mancy from months to decades while they adapt to their 
new found microenvironment. Cancer cells undergo mes-
enchymal-to-epithelial transition (MET) in order to 
acquire feature proliferation to metastatic outgrowth in 
the target site
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4.2.1.2  Role in Therapy Resistance
Increased expression of Cav-1 can promote 
development of resistance to chemo- or radio-
therapy [14, 17]. In cisplatin-resistant ovarian 
cancer cells, both expression levels of Cav-1 and 
its mRNA transcript were significantly higher 
than those in normal ovarian cancer cells [32]. 
Knockdown of Cav-1 sensitized cisplatin- 
resistant ovarian cancer cells to apoptosis, which 
was attributable to downregulation of expression 
of Notch-1, p-Akt, and p-NF-κB/p65 [32].
4.2.1.3  Role in Cancer Stem Cells (CSCs)
CSCs represent an important subset of TME 
components. CSCs are responsible for tumor ini-
tiation, metastasis, and recurrence as well as 
resistance to chemo- and radiotherapy, which are 
associated with poor clinical outcomes. Because 
CSCs contribute to cancer development and pro-
gression, the presence of CSC population in pre-
cancerous stage is an early indicator of malignant 
progression. Some biological mediators (e.g., 
nitric oxide; NO) found in the TME could pro-
mote manifestation of CSC-like phenotypes of 
human nonsmall-cell lung carcinoma via Cav-1 
upregulation [33].
Our recent study revealed that Cav-1 expres-
sion is significantly lower in tumorspheres 
derived from human breast cancer 
(MDA-MB-231) cells than in adherent cells [34]. 
In line with this notion, silencing of Cav-1 
enhanced stemness of MDA-MB-231  cells as 
evidenced by the increased proportion of CD44high 
and CD24low cells. Notably, Src-mediated phos-
phorylation of Cav-1 at the Tyr 14 residue was 
found to be essential for its destabilization via the 
ubiquitin-proteasome degradation system which 
accounts for the reduced Cav-1 in a breast CSC- 
like state [34].
4.2.2  Tumor Suppressive Function
In some tissues, Cav-1 has been shown or specu-
lated to function as a tumor suppressor. Several 
studies have shown that Cav-1 inhibits colony 
formation and induces apoptosis in transformed 
cells and cancerous cells [35–37]. In addition, 
forced reexpression of Cav-1 abrogated 
anchorage- independent growth of transformed 
cells [35–39].
In human breast cancer, the Cav-1 has been 
considered a tumor suppressor gene associated 
with inhibition of tumor metastasis. Sagara and 
colleagues investigated the mRNA and protein 
expression levels of Cav-1 in 162 cases of breast 
cancer and found that the Cav-1 expression was 
suppressed at both transcriptional and transla-
tional levels in breast cancer tissues compared 
with the normal tissues [40]. In this study, the 
reduced Cav-1 mRNA level was significantly 
associated with an increased tumor size, and was 
correlated with hormonal receptor status [40]. 
Overexpressed Cav-1 reduced the invasion 
capacity of metastatic mammary tumor cells by 
inhibiting the activity of MMP-2 and MMP-9 
[41]. In normal breast, Cav-1 was found to be 
expressed in myoepithelial cells, endothelial 
cells, and a subset of fibroblasts. In contrast, 
luminal epithelial cells showed negligible stain-
ing [42].
Low levels of Cav-1 and its mRNA transcripts 
were detected in several colon carcinoma cell 
lines. Moreover, Cav-1 protein levels were mark-
edly lower in human colon tumor epithelium than 
in normal colon mucosa. Ectopic expression  of 
Cav-1  in the colon carcinoma cells attenuated 
tumor formation when these cells were inocu-
lated into nude mice [43]. Moreover, Cav-1 may 
function as a negative regulator of metastasis by 
inhibiting MT4-MMP expression in colon cancer 
[44]. Cav-1 is not expressed in lipid rafts of the 
highly metastatic colon cancer cell line, but 
expressed in cytosolic fractions of the parental 
lower metastatic cell line. Xenografting Cav-1 
deficient cells in nude mice induced development 
of bigger tumors expressing higher levels of pro-
liferating cell nuclear antigen than in mice 
injected with cells expressing the higher level of 
Cav-1 [45]. In another study, high Cav-1 expres-
sion correlated with good clinical outcomes in 
head and neck cancer and extrahepatic biliary 
carcinoma cells [46]. In mucoepidermoid carci-
noma of the salivary glands, reduced expression 
of Cav-1 was associated with a poor prognosis 
for some patients [45].
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Contrary to the previous report on the associa-
tion between Cav-1 and Rho-GTPases that pro-
motes tumor metastasis [29], Lin and colleague 
have reported that Cav-1 expression inhibits 
RhoC GTPase activation and subsequently acti-
vates the p38 mitogen-activated protein kinase, 
leading to suppression of migration and invasion 
of primary pancreatic cancer cells [47].
In in vivo experiments, Cav-1 knockout mice 
showed increased development or progression of 
some cancers. A novel mouse model of colorectal 
cancer was generated by crossing C57BL/6 
Apcmin/+ with B6129 Cav-1 knockout (Cav1−/−) 
mice. Absence of Cav-1 accelerated colorectal 
tumorigenesis in Apcmin/+ mice, which was 
accompanied by upregulation of Wnt signaling 
[48].
Cav-1 null mice are much more susceptible to 
chemically induced skin carcinogenesis as well 
as epidermal hyperplasia than wild-type litter-
mates [49]. In addition, cyclin D1 expression was 
upregulated during epidermal hyperplasia, which 
may account for the increased susceptibility of 
Cav-1 null mice to skin paillomagenesis [49]. 
Further, orthotopic implantation of B16F10 mel-
anoma cells in the skin of Cav-1 null mice 
increased tumor growth [50].
Lewis lung carcinoma cells implanted into 
Cav-1 knockout mice had increased tumor vascu-
lar permeability compared with tumors implanted 
into wild-type mice. Cav-1 deficient mice also 
had significantly higher tumor growth rates, and 
this  was  attributable to increased tumor angio-
genesis and decreased tumor cell death [51].
4.3  Stromal Versus Tumoral 
Cav-1 in TME
There has been increasing concern about the 
tumor-host interactions, which influence tumor 
growth, metastasis, therapy resistance, and cell 
survival. Understanding such tumor-stroma com-
munication interactions may hence offer a novel 
therapeutic strategy to avoid or minimize therapy 
resistance and improve clinical outcomes [14].
Multiple lines of compelling evidence support 
that the heterogeneous tumor stroma in TME 
contributes to manifestation of a malignant phe-
notype of epithelial tumors, tumor recurrence, 
metastasis, and therapy resistance, resulting in 
poor clinical outcome. In this context, Cav-1  in 
the stroma of TME is also likely to be an impor-
tant prognostic indicator of breast cancer [12, 
14]. An absence or reduced stromal Cav-1 expres-
sion accounts for poor clinical outcome or ther-
apy resistance in many different types of cancers 
[12, 13, 52–54].
4.3.1  Cav-1 in Cancer-Associated 
Fibroblasts
The stroma which constitutes at least half of the 
tumor mass consists of cancer-associated fibro-
blasts (CAFs), macrophages and other immune 
cells, and endothelial cells. Of the stromal cells, 
CAFs play a key role in tumor-stromal interac-
tion. Loss of Cav-1 expression in CAFs results in 
an activated TME, thereby driving early tumor 
recurrence, metastasis, and poor clinical outcome 
in various malignancies [12]. The loss of Cav-1 in 
fibroblasts is sufficient to induce a CAF pheno-
type. In addition to CAFs, metastasis-associated 
macrophages in TME also express abundant lev-
els of Cav-1, which is critical for metastasis and 
not for primary tumor growth [55]. The decreased 
expression of Cav-1 in CAFs resulted in a growth 
advantage and the chemoresistance of cancer 
cells when they were co-injected into immunode-
ficient mice to develop mixed fibroblast/cancer 
cell xenografts [56]. In this study, however, Cav-1 
downregulation in cancer cells had no effect on 
chemoresistance and growth gain in vivo. Thus, it 
is likely that relative expression of tumor vs. stro-
mal Cav-1 in TME has more precise prognostic 
significance than that of each alone. In this con-
text, it is interesting to note that low expression of 
stromal Cav-1 was negatively associated with 
cytoplasmic Cav-1 expression in total tumor tis-
sues [57]. As the colon tumor becomes more 
aggressive and metastatic, it  looses the stromal 
Cav-1 and gains the cellular Cav-1 as well as the 
abnormal β-catenin expression [58]. In line with 
this notion,  the high tumor/low stromal expres-
sion of Cav-1 was closely associated with poor 
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prognostic outcomes in primary human pros-
tate cancer patients [59].
Sotgia and colleagues have proposed para-
crine signaling mechanisms by which the loss of 
stromal Cav-1 promotes tumor progression to 
fuel the growth of adjacent tumor cells [12]. It 
appears that oxidative stress is the root cause of 
initiation of the loss of stromal Cav-1 via autoph-
agy [12]. It is noteworthy that loss of stromal 
Cav-1 correlates with high epithelial Cav-1 levels 
and activated Akt [60]. Low stromal expression 
of Cav-1 increased TGF-β1 expression and 
induced phosphorylation and activation of Akt in 
human dermal fibroblasts [61].
Though the majority of studies suggest stro-
mal Cav-1, especially of CAF origin, has tumor 
suppressive functions, Cav-1 expression of CAFs 
has been shown to be associated with patients’ 
poor prognosis [62, 63]. Moreover, tumors with 
Cav-1-positive CAFs had vascular and pleural 
invasion significantly more frequently than those 
with Cav-1-negative CAF [64].
4.3.2  Cav-1 in Other Stromal Cells
Besides CAFs, Cav-1 may also functions in some 
other stromal cells in TME. Cav-1 is abundant in 
endothelial cells, adipocytes, and smooth muscle 
cells as well as in fibroblasts and epithelial cells. 
Several studies have suggested that Cav-1 may 
function in the main types of vascular cells in 
TME [51, 65–67], including pericytes, endothe-
lial cells, and smooth muscle cells which are 
associated with vascular permeability and mor-
phogenesis in tumor. Endothelial cells play a cen-
tral role in angiogenesis, a process by which new 
vasculature is derived from preexisting blood 
vessels. Several studies have proposed a role for 
Cav-1 in the regulation of vascular development 
and angiogenesis [51, 65–67].
Under physiological condition, the main func-
tion of Cav-1 is to inhibit endothelial permeabil-
ity. Cav-1 knockout mice were observed to 
exhibit a hyperpermeable vascular endothelium 
[66].  Likewise, tumors grown in Cav1−/− mice 
became leaky as evidenced by increased tumor 
vascular permeability, and grew faster, compared 
with tumors implanted into wild-type mice [51]. 
Cav-1 deficient  mice also displayed  elevated 
tumor angiogenesis and decreased tumor cell 
death, which may account for significantly higher 
tumor growth rates [51]. As Cav-1 is an endoge-
nous inhibitor of endothelial NO synthase 
(eNOS), the loss of Cav-1 may result in hyperac-
tivation of eNOS, and resultant NO overproduc-
tion is speculated to increase tumor vascular 
permeability, survival, and ultimately tumor 
growth [51]. Besides inhibition of endothelial 
NO production, there might be an alternative 
mechanism by which Cav-1 modulates the micro-
vascular permeability and angiogenesis. Cav-1 
has been found to interact with many intracellular 
signaling molecules including receptors, thereby 
altering their activity.  For instance, Cav-1 sup-
presses  vascular endothelial cell growth factor 
receptor (VEGFR)-2 signaling by inhibiting tyro-
sine phosphorylation of this receptor mediated 
by adherens junction protein, VE cadherin [51]. 
Therefore, the enhanced tumor permeability and 
growth as a consequence of loss of Cav-1 may be 
attributed to augmented proangiogenic signaling 
through inhibition of phosphorylation-dependent 
VEGFR-2 activation [51].
Soon after microvessels are formed, they 
come in close contact with mural cells of the 
smooth muscle cell lineage, referred to as peri-
cytes or vascular smooth muscle cells. Such asso-
ciation of pericites (smooth muscle cells) with 
endothelial cells lining newly formed blood ves-
sels is essential for vascular development and sta-
bility [68]. Cav-1 was found to be enriched in the 
lipid raft fraction of pericytes [69]. Cav-1 
impaired the migration of pericytes [66]. 
Therefore, a decrease in Cav-1 abundance 
appears to stimulate the angiogenesis and prevent 
its termination by mural cell recruitment [66]. In 
another study, a cell-permeable peptide derived 
from the Cav-1 scaffolding domain inhibited the 
proliferation of pericytes, but not their survival or 
migration [67].
There is paucity of information on the role of 
Cav-1, derived from other stromal cells of TME, 
in cancer development and progression. Cav-1 
promotes differentiation of monocytes to mac-
rophages [70]. Downregulated Cav-1 expres-
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sion in circulating monocytes has been 
implicated in the pathogenesis of psoriasis [71]. 
However, the functional role of Cav-1 in stromal 
macrophages in TME has been poorly under-
stood. It has been reported that Cav-1 functions 
as an anti- metastatic regulator in mouse models 
of lung and breast cancer pulmonary metastasis 
[54]. Among all the recruited inflammatory cell 
populations, metastasis- associated macrophages 
(MAMs) uniquely express high levels of Cav-1. 
Loss of Cav-1 did not affect MAM recruitment 
to the metastatic site, but rather favored lung 
metastatic growth through increased angiogen-
esis [54].





Recent studies have highlighted the importance 
of Cav-1, especially of stromal origin, in meta-
bolic alterations in cancer cells in relation to their 
survival advantage. Cav-1 influences tumor 
development or progression by modulating such 
metabolic pathways as glycolysis, mitochondrial 
bioenergetics, glutaminolysis, fatty acid metabo-
lism, etc. [13]. Catabolic CAFs represent a key 
metabolic “fuel source,” required for cancer cell 
propagation, survival, and systemic dissemina-
tion during metastasis [52]. A loss of Cav-1 has 
been shown to drive the metabolic reprogram-
ming of stromal cells to support the growth of 
adjacent epithelial tumor cells. Stromal cells 
could function as providers of energy metabolites 
for tumor cells by undergoing the “reverse 
Warburg effect” [53]. The interaction between 
the tumoral microvesicles (TMVs) and stroma in 
the tumor microenvironment plays a critical role 
in facilitating cancer progression. After being 
incubated with tumoral microvesicles, normal 
human gingival fibroblasts acquired a phenotype 
switch to CAFs which was accompanied by deg-
radation of Cav-1 [72]. Notably, Cav-1-deficient 
CAFs undergo autophagy to secrete energy-rich 
metabolites and chemical building blocks that 
can sustain and support the growth of tumor 
cells [12].
Some studies also revealed the critical role of 
oxidative stress in a loss of stromal Cav-1 and the 
metabolic reprogramming of CAFs [73]. 
Although Cav-1 loss is caused by elevated ROS 
levels, Cav-1 downregulation may result in 
increased oxidative stress, which represents a 
feed-forward mechanism [12]. Oncogenes drive 
the onset of the CAF phenotype in adjacent nor-
mal fibroblasts by provoking  oxidative stress. 
This oncogene-triggered fibroblast activation is 
“mirrored” by a loss of stromal Cav-1. These 
fibroblasts exhibit elevated ROS production and 
elevated glucose uptake, indicative of a shift 
toward a glycolytic metabolism [52].
4.5  Conclusion
As a main component of caveolae, Cav-1 is 
involved in many biological processes that 
include substance uptake and transmembrane 
signaling. In addition, Cav-1 can modulate can-
cer cell proliferation, differentiation, migration, 
invasion, metastasis, and resistance to anticancer 
therapy.
Although the role of Cav-1  in cancer is still 
elusive, the majority of reports suggest that Cav-1 
represents an important prognostic marker of 
tumor development and progression, and inde-
pendently serves as a predictor of overall survival 
rate. In addition, through interaction with other 
biological molecules, Cav-1 modulates stem-like 
traits. On the other hand, a functional loss of 
Cav-1 in several tumor cells induces a hyperpro-
liferative state, promoting cell proliferation, sur-
vival, and invasiveness as well as acquisition of 
resistance to cancer therapy [14].
Based on these findings, the roles for Cav-1 in 
human cancer and its suitability as a prognostic 
marker are controversial. Cav-1 is likely to func-
tion both as a tumor suppressor and as an oncop-
rotein, depending on the stage of neoplastic 
transformation and extent of tumor progression 
(Fig. 4.3). Though Cav-1 appears to be downreg-
ulated in early transformed cells, a reexpression 
or rather upregulation and stabilization through 
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phosphorylation of Cav-1, in later tumor stages, 
may confer invasiveness, resistance, and survival 
advantage of multidrug-resistant tumor cells [14].
The differential effects of Cav-1  in tumor 
development and progression may be related to a 
different profile of TME components involved in 
each stage of cancer, particularly in the context of 
tumor vs. stromal form of Cav-1. Loss of stromal 
Cav-1  in TME has been frequently associated 
with poor patient outcomes in diverse malignan-
cies. A characteristic shift in stromal-epithelial 
Cav-1  in advanced and metastatic tumor stages 
with a loss of stromal Cav-1 and a concomitant 
increase in expression of epithelial isoform high-
lights Cav-1 as being a tissue and stage-specific 
tumor modulator [14]. A molecular mechanism 
by which Cav-1 expression is upregulated/
restored in more advanced stages of cancer and 
how Cav-1 deficient CAFs promote this process 
merit further investigation. Identification and 
characterization of CAF-derived signaling mole-
cules that mediate the shift in stromal-tumor 
Cav-1 accumulation during cancer progression 
will be of particular interest. Another interesting 
research subject would be  elucidation of how 
metabolic reprogramming of Cav-1 deficient 
CAFs by CAF-addicted cancer cells is achieved.
Further studies are required to unveil the clini-
cal value of Cav-1 as a prognostic marker and a 
candidate target for cancer therapy.
Acknowledgment This study was supported by the 
Global Core Research Center (GCRC) grant (No. 2011- 
0030001) from the National Research Foundation (NRF) 
of Republic of Korea.
References
 1. Anderson RG (1998) The caveolae membrane system. 
Annu Rev Biochem 67:199–225
 2. Lamaze C, Torrino S (2015) Caveolae and cancer: a 
new mechanical perspective. Biom J 38:367–379
 3. Bender F, Montoya M, Monardes V, Leyton L, Quest 
AF (2002) Caveolae and caveolae-like membrane 
domains in cellular signaling and disease: identifica-
tion of downstream targets for the tumor suppressor 
protein caveolin-1. Biol Res 35:151–167
Differentiation
Tumor suppressor






















Fig. 4.3 Dual role of Cav-1 in cancer. Cav-1 may func-
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drug-resistant form is associated with reexpression of 
Cav-1. Upregulation of Cav-1 in these tumors is thought 
to contribute to tumor cell invasiveness and resistance to 
anoikis, properties that are essential for tumor cell metas-
tasis. Increased Cav-1 has also been associated with the 
development of drug resistance in tumors
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